The OsteoArthritis Centers of America and Gensco Laboratories have entered into a collaborative research agreement to improve OA Centers of America's proprietary algorithm for the treatment of pain conditions.

Under the deal, OA Centers of America will include Gensco's patented Transdermal products (SpeedGel Rx and LiDORx) as an option to show improved patient outcomes and economic value of treating specific types of pain with transdermal technology.

Results from this research will be published to share and improve treatment approaches globally.

Gensco Labs president and CEO Carlos Alfaras said: "There is a clear need for non-narcotic pain control options for patients.

"We are excited to collaborate with OA Centers of America, a proven leader in treating patients with osteoarthritis and musculoskeletal pain.

"Their strong commitment to developing outcomes driven clinical programs has provided an ideal opportunity to work together to improve patient care."

OA Centers of America has created outcomes driven clinical programs focused on non-surgical, FDA approved treatments for chronic pain in knees, hips, shoulders, and back, peripheral neuropathies, and other conditions.

Gensco is a pharmaceutical manufacturer focused on the research, development and marketing of transdermal prescription medications.